Factor V Inhibitors: A Diagnostic and Therapeutic Challenge

Area of Science:

• Hematology
• Coagulation Science

Background:

• Factor V inhibitors historically arose from bovine thrombin use in surgery.
• Incidence has decreased with newer hemostatic agents but remains a concern.
• Inhibitors can occur idiopathically or with medications, malignancies, autoimmune disorders, pregnancy, or infections.

Purpose of the Study:

• To review the role of platelet and plasma Factor V in hemostasis.
• To discuss the characteristics, clinical features, diagnosis, treatment, and prognosis of Factor V inhibitors.

Main Methods:

• Literature review of Factor V inhibitors.
• Analysis of clinical presentations and management strategies.

Main Results:

• Factor V inhibitors can manifest as severe bleeding or thrombosis, or be found incidentally.
• Diagnosis relies on coagulation screening abnormalities.
• Management is complex, requiring bleeding control and inhibitor eradication.

Conclusions:

• Factor V inhibitors, while less frequent, pose significant clinical challenges.
• Understanding their diverse causes and presentations is crucial for effective patient management.